<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - RIBAVIRIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>RIBAVIRIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#lessSuitableForPrescribing" data-toggle="tab">Less suitable for prescribing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Bronchiolitis</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of aerosol or by inhalation of nebulised solution</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 1 month&#8211;2 years</strong><br/>
                Inhale a solution containing 20 mg/mL for 12&#8211;18 hours for at least 3 days, maximum of 7 days, to be administered via small particle aerosol generator.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Life-threatening RSV, parainfluenza virus, and adenovirus infection in immunocompromised children (administered on expert advice)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children </strong><br/>
                33 mg/kg for 1 dose, to be administered over 15 minutes, then 16 mg/kg every 6 hours for 4 days, then 8 mg/kg every 8 hours for 3 days.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid; teratogenicity in <i>animal</i> studies.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Pregnant women should avoid exposure to aerosol.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>No dosage adjustment required.</p>
            </section>
            <section class="generalInformation">
              <p>Avoid oral ribavirin in severe hepatic dysfunction or decompensated cirrhosis.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Plasma-ribavirin concentration increased.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">In adults</h3>
              <p>Manufacturer advises avoid oral ribavirin unless essential if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;monitor haemoglobin concentration closely.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">In children</h3>
              <p>Manufacturer advises avoid oral ribavirin if estimated glomerular filtration rate less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;monitor haemoglobin concentration closely.</p><p>Manufacturer advises use intravenous preparation with caution if estimated glomerular filtration rate less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> bacterial pneumonia, haemolysis, non-specific anaemia, pneumothorax, worsening respiration, abdominal pain, abnormal dreams, acne, alopecia, angina in adults, anorexia in adults, anxiety, aplastic anaemia, arrhythmias, arthralgia, asthenia in children, asthenia in children, ataxia, bipolar disorders in adults, breast pain, cardiomyopathy, cerebral haemorrhage in adults, cerebral ischaemia in adults, changes in blood pressure, cheilitis, chest pain, colitis, constipation, cough, dehydration, depression, diabetes in adults, diarrhoea, dizziness, dry eyes, dry mouth, dry skin, dyspepsia, dysphagia, dysphonia in children, dyspnoea, earache, endocarditis in adults, epistaxis in children, eye pain, flatulence, flushing, gastro-intestinal bleeding, gastroesophageal reflux in children, gingival bleeding in adults, gingivitis, glossitis, growth retardation (including decrease in height and weight) in children, haemolytic anaemia (anaemia may be improved by epoetin), hallucination in children, headache, hearing impairment, hearing loss in adults, hyperaesthesia, hyperglycaemia, hyperkinesia in children, hypertonia, hypertriglyceridaemia, hyperuricaemia, hypoaesthesia, hypocalcaemia, impaired concentration and memory, increased sweating, influenza-like symptoms, interstitial pneumonitis, leucopenia, loose stools in children, lymphadenopathy, malaise in adults, mania in adults, menstrual disturbance, micturition disorders, mood disorders in children, mouth ulcers, musculoskeletal pain, myalgia, myocardial infarction, myositis in adults, nasal congestion, nausea, neutropenia, optic neuropathy, oral candidiasis, pallor in children, palpitation, pancreatitis, panic attack in children, paraesthesia, peptic ulcer, pericarditis, peripheral ischaemia in children, peripheral neuropathy, peripheral oedema, photosensitivity, prostatitis in adults, pruritus, psoriasis, psychotic disorders, pulmonary embolism, rash, renal failure, respiratory infections, retinal detachment in adults, retinal haemorrhage, rhabdomyolysis in adults, rheumatoid arthritis, sarcoidosis, seizures, sexual dysfunction, sinus congestion, skin discoloration, sleep disturbances, sore throat, Stevens-Johnson syndrome, stomatitis, stroke in children, suicidal ideation (more frequent in children), syncope, systemic lupus erythematosus, tachycardia, tachypnoea in children, taste disturbance, testicular pain in children, thrombocytopenia, thrombocytopenia purpura in adults, thyroid disorders, tinnitus, tongue pigmentation in adults, tooth disorder in children, toxic epidermal necrolysis, tremor in adults, urinary tract infections, vaculitis in adults, vertigo in children, virilism in children, vision loss in adults, visual disturbances, vomiting, weight loss, wheezing,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Side effects listed are reported when oral ribavirin is used in combination with peginterferon alfa or interferon alfa, consult product literature for details.</p>
            </section>
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA200</h3>
              <p outputclass="specificity">In adults</p> <p outputclass="title">Peginterferon alfa and ribavirin for mild chronic hepatitis C (August 2006 and September 2010)</p> <p>The combination of peginterferon alfa and ribavirin can be used for treating mild chronic hepatitis C in patients over 18 years. Alternatively, treatment can be delayed until the disease has reached a moderate stage (&#8216;watchful waiting&#8217;).</p><xref format="html" href="http://www.nice.org.uk/TA200">www.nice.org.uk/TA200</xref>
                <a href="http://www.nice.org.uk/TA200" target="_blank">www.nice.org.uk/TA200</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA200</h3>
              <p outputclass="specificity">In adults</p> <p outputclass="title">Peginterferon alfa, interferon alfa, and ribavirin for moderate to severe chronic hepatitis C (January 2004 and September 2010)</p> <p>The combination of peginterferon alfa and ribavirin should be used for treating moderate to severe chronic hepatitis C in patients aged over 18 years: . </p> <ul> <li>not previously treated with interferon alfa or peginterferon alfa;</li> <li>treated previously with interferon alfa alone or in combination with ribavirin;</li> <li>whose condition did not respond to peginterferon alfa alone or to a combination of peginterferon alfa and ribavirin, or responded but subsequently relapsed;</li> <li>co-infected with HIV.</li> </ul> <p>Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Interferon alfa for either monotherapy or combined therapy should be used only if neutropenia and thrombocytopenia are a particular risk. Patients receiving interferon alfa may be switched to peginterferon alfa.</p><xref format="html" href="http://www.nice.org.uk/TA200">www.nice.org.uk/TA200</xref>
                <a href="http://www.nice.org.uk/TA200" target="_blank">www.nice.org.uk/TA200</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA300</h3>
              <p outputclass="specificity">In children</p> <p outputclass="title">Peginterferon alfa and ribavirin for chronic hepatitis C (November 2013)</p> <p>Peginterferon alfa in combination with ribavirin is recommended (within the marketing authorisation) as an option for treating chronic hepatitis C in children.</p><xref format="html" href="http://www.nice.org.uk/TA300">www.nice.org.uk/TA300</xref>
                <a href="http://www.nice.org.uk/TA300" target="_blank">www.nice.org.uk/TA300</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>When used by inhalation:</strong>
            maintain standard supportive respiratory and fluid management therapy
          </li>
          <li>
              <strong>With systemic use:</strong>
            anaemia (haemoglobin concentration should be monitored during the treatment and corrective action taken) in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            cardiac disease (assessment including ECG recommended before and during treatment&#8212;discontinue if deterioration)
          </li>
          <li>
              <strong>With systemic use:</strong>
            consult product literature for specific cautions when <xref format="dita" href="#PHP3904" type="drug" namespace="/drugs/ribavirin">ribavirin</xref> used in combination with other medicinal products
          </li>
          <li>
              <strong>With systemic use:</strong>
            gout in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            haemolysis (haemoglobin concentration should be monitored during the treatment and corrective action taken) in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            patients with a transplant&#8212;risk of rejection
          </li>
          <li>
              <strong>With systemic use:</strong>
            risk of growth retardation in children, the reversibility of which is uncertain&#8212;if possible, consider starting treatment after pubertal growth spurt in children
          </li>
          <li>
              <strong>With systemic use:</strong>
            severe dental disorders in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            severe ocular disorders in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            severe periodontal disorders in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            severe psychiatric effects in adults
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Exclude pregnancy before treatment in females of childbearing age.</p><p>Effective contraception essential during treatment and for 4 months after treatment in females and for 7 months after treatment in males of childbearing age.</p><p>Routine monthly pregnancy tests recommended.</p><p>Condoms must be used if partner of male patient is pregnant (ribavirin excreted in semen).</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Women planning pregnancy should avoid exposure to aerosol.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Monitor electrolytes closely.</p><p>Monitor equipment for precipitation.</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in children</h3>
              <p>Determine full blood count, platelets, electrolytes, serum creatinine, liver function tests and uric acid before starting treatment and then on weeks 2 and 4 of treatment, then as indicated clinically&#8212;adjust dose if adverse reactions or laboratory abnormalities develop (consult product literature).</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in adults</h3>
              <p>Determine full blood count, platelets, electrolytes, glucose, serum creatinine, liver function tests and uric acid before starting treatment and then on weeks 2 and 4 of treatment, then as indicated clinically&#8212;adjust dose if adverse reactions or laboratory abnormalities develop (consult product literature).</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in children</h3>
              <p>Test thyroid function before treatment and then every 3 months.</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Eye examination recommended before treatment.</p><p>Eye examination also recommended during treatment if pre-existing ophthalmological disorder or if decrease in vision reported&#8212;discontinue treatment if ophthalmological disorder deteriorates or if new ophthalmological disorder develops.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph> in children</h3>
              <p>Inhalation licensed for use in children (age range not specified by manufacturer).</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>Intravenous preparation not licensed.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Flavours of oral liquid formulations may include bubble-gum.</p>
            </section>
      </section>



      <section class="tab-pane" id="lessSuitableForPrescribing">
        <h2>Conditions when less suitable for prescribing</h2>

            <section class="lessSuitableForPrescribing">
              <p>Ribavirin inhalation is less suitable for prescribing.</p>
            </section>
      </section>






      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of RIBAVIRIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76580"><a href="../medicinalForm/PHP76580.html" data-target="#PHP76580" data-action="load">Tablet</a></div>
            <div id="PHP76565"><a href="../medicinalForm/PHP76565.html" data-target="#PHP76565" data-action="load">Capsule</a></div>
            <div id="PHP76587"><a href="../medicinalForm/PHP76587.html" data-target="#PHP76587" data-action="load">Oral solution</a></div>
            <div id="PHP76593"><a href="../medicinalForm/PHP76593.html" data-target="#PHP76593" data-action="load">Solution for injection</a></div>
            <div id="PHP76572"><a href="../medicinalForm/PHP76572.html" data-target="#PHP76572" data-action="load">Powder for nebuliser solution</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
